Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

Authors

Omid Hamid

The Angeles Clinic and Research Institute, Los Angeles, CA

Omid Hamid , Laura Quan Man Chow , Fatemeh Tavakkoli , Shannon Marshall , Matthew Joseph Gribbin , Joyson Joseph Karakunnel , Jhanelle Elaine Gray

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.

First Author: Haruo Iguchi

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.

First Author: Patrick Alexander Ott

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.

First Author: Guillermo Garcia-Manero

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

First Author: Elena Garralda